Insmed (INSM) TPIP Data Keeps Bull Case Alive As Valuation Debate Builds

Why the latest TPIP data matters for Insmed stock

Insmed (INSM) is back in focus after releasing 12 month open label extension data for its treprostinil palmitil inhalation powder in pulmonary arterial hypertension, alongside a special call to walk investors through the results.

The update highlighted sustained effects on six minute walk distance, cardiac stress biomarkers, and World Health Organization Functional Class, together with a long term safety profile that management believes supports the recently launched Phase 3 PALM PAH study.

See our latest analysis for Insmed.

Insmed's TPIP update landed after a period where the share price has been under pressure, with the stock down 39.63% year to date and 21.37% over 3 months, yet still showing a very large 3 year total shareholder return above 7x.

If this kind of clinical momentum has you thinking about other long term ideas in healthcare and biotech, it can be useful to broaden your search with 18 top founder-led companies

Bulls point to Insmed's TPIP momentum and the wide gap to analyst price targets, while bears focus on the ongoing losses and recent share price slide. Which side does the current valuation actually support?

Most Popular Narrative: 45.8% Undervalued

At a last close of $106.92 against a most popular fair value estimate of about $197.14, Insmed is framed as materially undervalued in that narrative, with the gap tied directly to ambitious growth and profitability assumptions.

The anticipated U.S. launch of brensocatib in bronchiectasis in the third quarter of 2025 is a major catalyst, expected to significantly increase revenue once it hits the market and starts generating sales late in Q3. The upcoming Phase II data for TPIP in PAH by mid 2025 and brensocatib in CRS without nasal polyps by the end of 2025 are key clinical milestones that could enhance future revenue streams if positive.

Read the complete narrative.

Want to see how this story moves from heavy losses to strong profits and a premium future multiple? The narrative leans on rapid revenue expansion, sharply improving margins and a rich earnings valuation that many investors usually associate with much larger compounders.

Result: Fair Value of $197.14 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Insmed story also hinges on timely regulatory decisions and payer support for brensocatib, as delays or tougher reimbursement could quickly challenge this optimistic setup.

Find out about the key risks to this Insmed narrative.

Another View: What Insmed's P/S Ratio Is Telling You

While the popular Insmed narrative leans heavily on future cash flows and analyst fair value, the current P/S ratio paints a very different picture. At about 28.3x sales versus 10.8x for the US Biotechs industry and 8.7x for peers, the stock is priced well above its group.

Even against an estimated fair ratio of 19.9x, Insmed screens as expensive. This suggests there may be less room for error if revenue or margins land below expectations. With that kind of gap, it is worth asking whether investors are being compensated adequately for the execution and funding risks that remain in the story.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed sentiment around Insmed has you unsure which way to lean, take a moment to review both the potential benefits and the key risks by checking 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Insmed?

If the Insmed story has you thinking bigger about your portfolio, do not stop at one stock. Widen your search now before the next opportunity passes you by.

• Spot potential bargains early and see which companies combine quality with attractive pricing by starting with 49 high quality undervalued stocks
• Shield your capital from unnecessary shocks by focusing on sturdier companies featured in the 79 resilient stocks with low risk scores
• Hunt for under-followed opportunities that still show solid fundamentals by checking the screener containing 19 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com